P40.20 Real-Life Analysis of Immunotherapy as the Second or Later Lines Treatment in Patients With Metastatic Non-Small Cell Lung Cancer

2021 ◽  
Vol 16 (10) ◽  
pp. S1078
Author(s):  
S.G. Aydin ◽  
Y. Kutlu ◽  
O. Acikgoz ◽  
A. Bilici ◽  
J. Hamdard ◽  
...  
2021 ◽  
Vol 54 (3) ◽  
pp. 281-290
Author(s):  
Sabin Göktaş Aydın ◽  
Özgür Açıkgöz ◽  
Yasin Kutlu ◽  
Ahmet Bilici ◽  
Jamshid Hamdard ◽  
...  

Lung Cancer ◽  
2019 ◽  
Vol 127 ◽  
pp. 96-102 ◽  
Author(s):  
Jean Bernard Auliac ◽  
Maurice Pérol ◽  
David Planchard ◽  
Isabelle Monnet ◽  
Marie Wislez ◽  
...  

Lung Cancer ◽  
2018 ◽  
Vol 126 ◽  
pp. 217-223 ◽  
Author(s):  
Elizabeth Dudnik ◽  
Mor Moskovitz ◽  
Sameh Daher ◽  
Sivan Shamai ◽  
Ekaterina Hanovich ◽  
...  

2018 ◽  
Vol 34 (9) ◽  
pp. 1687-1694 ◽  
Author(s):  
Vítězslav Kolek ◽  
Stanislav Losse ◽  
Juraj Kultan ◽  
Petr Jakubec ◽  
Zatloukal Jaromir ◽  
...  

Lung Cancer ◽  
2020 ◽  
Vol 139 ◽  
pp. S10
Author(s):  
D. Reed ◽  
E. Shaw ◽  
S. Savory ◽  
R. Panchal ◽  
S. Agrawal ◽  
...  

Immunotherapy ◽  
2020 ◽  
Vol 12 (4) ◽  
pp. 235-243 ◽  
Author(s):  
Daniel Reinhorn ◽  
Oded Jacobi ◽  
Oded Icht ◽  
Elizabeth Dudnik ◽  
Ofer Rotem ◽  
...  

Aim: The treatment paradigm of advanced non-small-cell lung cancer has recently changed with the introduction of immune checkpoint inhibitors (ICIs). It is common practice to continue treatment beyond progression (TBP) in selected cases. The aim of this study was to evaluate real life practice and outcomes related to TBP. Materials & methods: We retrospectively evaluated advanced non-small-cell lung cancer patients treated with ICI therapy and identified patients who were treated beyond progression. Results: Of 207 patients included in this analysis, 22% patients received TBP. A total of 36% achieved a clinical benefit. A total of 27% patients had a progression-free interval over 6 months after receiving TBP. Conclusion: A subset of patients who were treated beyond progression with ICI achieved a clinically meaningful response with durable disease control.


2019 ◽  
Vol 145 (1) ◽  
pp. 85-95 ◽  
Author(s):  
Ariane Steindl ◽  
Franziska Schlieter ◽  
Thomas Klikovits ◽  
Elena Leber ◽  
Brigitte Gatterbauer ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document